OPCH Stock Alert: Halper Sadeh LLC is Investigating Whether Option Care Health, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC says it is investigating Option Care Health’s proposed sale to CD&R and McKesson for $32.05 per share. The article excerpt provides no findings or details of the investigation, and encourages Option Care shareholders to contact the firm.

Analysis

This is a law-firm investigation announcement, not evidence that a court has found misconduct or that the transaction is impaired. Its immediate information value is low; the meaningful risk is a later injunction, settlement condition, or delay that widens OPCH’s deal spread and reduces the annualized return to merger-arbitrage holders. The announcement does not establish the full transaction structure or McKesson’s precise role, so do not attribute incremental deal economics to MCK from this item alone.

Over the next 1–3 months, monitor a filed complaint, requested injunction, shareholder-vote developments, and any changes to consideration or closing conditions. A routine disclosure-focused resolution would likely have limited economic impact; a substantive challenge to the sale process could create timing risk even without changing the price. Over 6–18 months, the larger question is whether the buyer can close and realize its intended strategic value, which this announcement does not address.

Contrarian read: the headline may attract attention while overstating the probability of a deal break. The key missing inputs are OPCH’s current price, definitive agreement terms, termination protections, expected closing date, and the complaint’s actual allegations. Without these, there is no defensible spread or risk/reward estimate.

Key Decisions for Investors

• Do not trade OPCH solely on this solicitation. First verify whether a complaint has been filed and compare the live price with the $32.05 offer, accounting for time to close and deal-break risk.
• If holding OPCH as merger arbitrage, size exposure to tolerate a temporary spread widening; reassess promptly if an injunction is sought, the shareholder process is delayed, or consideration/closing terms change.
• Treat MCK as a watch item, not a direct trade from this announcement: confirm its contractual role and any disclosed funding, integration, or termination exposure before modeling earnings impact.
• Falsification of the low-impact base case: court action that threatens closing, a material adverse change in deal terms, or documented evidence of process deficiencies that prompts a buyer response.